Global Acute Disease Market

Acute Disease Comprehensive Study by Type (Acute minor illness (self-limiting), Acute major illness (self-limiting or requiring treatment), Acute presentation of existing major illness (acute exacerbation), Acute presentation of new chronic illness), Application (Children, Adult), End-User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028

Acute Disease Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Acute illnesses are those that are of short duration. They may be minor or they may be serious. Minor acute illnesses include some of the commonest problems presented in general practice, such as upper respiratory tract infections or skin rashes. Major acute illnesses may present as an acute exacerbation of an underlying chronic illness, such as a myocardial infarction or diabetic coma, or the sudden onset of a previously undiagnosed condition, such as epilepsy or stroke or an acute emotional or psychological problem.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline plc. (United Kingdom), Johnsons & Johnsons (United States), INO Therapeutics, LLC (United States), Octapharma AG (Switzerland), Ono Pharmaceutical Co., Ltd (Japan), Eli Lilly and Company (United States), Chiesi Farmaceutici S.p.A. (Italy), B. Braun Melsungen (Germany), Teva Pharmaceuticals (Israel), Dr. Reddy’s Laboratories (India) and Boehringer Ingelheim (Germany)


This growth is primarily driven by Increase in number of patients affected with acute disease and Increasing number of hospital.

Globally, a noticeable market trend is evident Increasing number of elderly people Major Players, such as GlaxoSmithKline plc. (United Kingdom), Johnsons & Johnsons (United States), INO Therapeutics, LLC (United States), Octapharma AG (Switzerland), Ono Pharmaceutical Co., Ltd (Japan), Eli Lilly and Company (United States), Chiesi Farmaceutici S.p.A. (Italy), B. Braun Melsungen (Germany), Teva Pharmaceuticals (Israel), Dr. Reddy’s Laboratories (India) and Boehringer Ingelheim (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market in new regions by expansions, investments, new service launches as their preferred strategies. Key players are exploring new geographies through expansions across the globe to avail competitive advantage through combined synergies.

Key Developments in the Market:
In April 2023, GlaxoSmithKline plc reaches an agreement to acquired late-stage biopharmaceutical company BELLUS Health. Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough
In July 2021, GlaxoSmithKline plc and Alector Global collaborated in immuno-neurology for two clinical-stage first-in-class monoclonal antibodies for neurodegenerative diseases. It co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease

Influencing Trend:
Increasing number of elderly people

Market Growth Drivers:
Increase in number of patients affected with acute disease and Increasing number of hospital

Challenges:
Lack of awareness regarding the treatment of acute disease

Restraints:
High cost for treatment

Opportunities:
Adoption of new technologies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Acute Disease Market
- Analysis about New Entrants in Acute Disease Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Acute Disease Study Sheds Light on
— The Acute Disease Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Acute Disease industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Acute Disease industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Acute minor illness (self-limiting)
  • Acute major illness (self-limiting or requiring treatment)
  • Acute presentation of existing major illness (acute exacerbation)
  • Acute presentation of new chronic illness
By Application
  • Children
  • Adult
By End-User
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in number of patients affected with acute disease
      • 3.2.2. Increasing number of hospital
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness regarding the treatment of acute disease
    • 3.4. Market Trends
      • 3.4.1. Increasing number of elderly people
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acute Disease, by Type, Application, End-User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Acute Disease (Value)
      • 5.2.1. Global Acute Disease by: Type (Value)
        • 5.2.1.1. Acute minor illness (self-limiting)
        • 5.2.1.2. Acute major illness (self-limiting or requiring treatment)
        • 5.2.1.3. Acute presentation of existing major illness (acute exacerbation)
        • 5.2.1.4. Acute presentation of new chronic illness
      • 5.2.2. Global Acute Disease by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adult
      • 5.2.3. Global Acute Disease by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Acute Disease Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Acute Disease (Price)
      • 5.3.1. Global Acute Disease by: Type (Price)
  • 6. Acute Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnsons & Johnsons (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. INO Therapeutics, LLC (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ono Pharmaceutical Co., Ltd (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Chiesi Farmaceutici S.p.A. (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. B. Braun Melsungen (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceuticals (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy’s Laboratories (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Boehringer Ingelheim (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Acute Disease Sale, by Type, Application, End-User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Acute Disease (Value)
      • 7.2.1. Global Acute Disease by: Type (Value)
        • 7.2.1.1. Acute minor illness (self-limiting)
        • 7.2.1.2. Acute major illness (self-limiting or requiring treatment)
        • 7.2.1.3. Acute presentation of existing major illness (acute exacerbation)
        • 7.2.1.4. Acute presentation of new chronic illness
      • 7.2.2. Global Acute Disease by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adult
      • 7.2.3. Global Acute Disease by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Acute Disease Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Acute Disease (Price)
      • 7.3.1. Global Acute Disease by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acute Disease: by Type(USD Million)
  • Table 2. Acute Disease Acute minor illness (self-limiting) , by Region USD Million (2017-2022)
  • Table 3. Acute Disease Acute major illness (self-limiting or requiring treatment) , by Region USD Million (2017-2022)
  • Table 4. Acute Disease Acute presentation of existing major illness (acute exacerbation) , by Region USD Million (2017-2022)
  • Table 5. Acute Disease Acute presentation of new chronic illness , by Region USD Million (2017-2022)
  • Table 6. Acute Disease: by Application(USD Million)
  • Table 7. Acute Disease Children , by Region USD Million (2017-2022)
  • Table 8. Acute Disease Adult , by Region USD Million (2017-2022)
  • Table 9. Acute Disease: by End-User(USD Million)
  • Table 10. Acute Disease Hospitals , by Region USD Million (2017-2022)
  • Table 11. Acute Disease Clinics , by Region USD Million (2017-2022)
  • Table 12. Acute Disease Others , by Region USD Million (2017-2022)
  • Table 13. South America Acute Disease, by Country USD Million (2017-2022)
  • Table 14. South America Acute Disease, by Type USD Million (2017-2022)
  • Table 15. South America Acute Disease, by Application USD Million (2017-2022)
  • Table 16. South America Acute Disease, by End-User USD Million (2017-2022)
  • Table 17. Brazil Acute Disease, by Type USD Million (2017-2022)
  • Table 18. Brazil Acute Disease, by Application USD Million (2017-2022)
  • Table 19. Brazil Acute Disease, by End-User USD Million (2017-2022)
  • Table 20. Argentina Acute Disease, by Type USD Million (2017-2022)
  • Table 21. Argentina Acute Disease, by Application USD Million (2017-2022)
  • Table 22. Argentina Acute Disease, by End-User USD Million (2017-2022)
  • Table 23. Rest of South America Acute Disease, by Type USD Million (2017-2022)
  • Table 24. Rest of South America Acute Disease, by Application USD Million (2017-2022)
  • Table 25. Rest of South America Acute Disease, by End-User USD Million (2017-2022)
  • Table 26. Asia Pacific Acute Disease, by Country USD Million (2017-2022)
  • Table 27. Asia Pacific Acute Disease, by Type USD Million (2017-2022)
  • Table 28. Asia Pacific Acute Disease, by Application USD Million (2017-2022)
  • Table 29. Asia Pacific Acute Disease, by End-User USD Million (2017-2022)
  • Table 30. China Acute Disease, by Type USD Million (2017-2022)
  • Table 31. China Acute Disease, by Application USD Million (2017-2022)
  • Table 32. China Acute Disease, by End-User USD Million (2017-2022)
  • Table 33. Japan Acute Disease, by Type USD Million (2017-2022)
  • Table 34. Japan Acute Disease, by Application USD Million (2017-2022)
  • Table 35. Japan Acute Disease, by End-User USD Million (2017-2022)
  • Table 36. India Acute Disease, by Type USD Million (2017-2022)
  • Table 37. India Acute Disease, by Application USD Million (2017-2022)
  • Table 38. India Acute Disease, by End-User USD Million (2017-2022)
  • Table 39. South Korea Acute Disease, by Type USD Million (2017-2022)
  • Table 40. South Korea Acute Disease, by Application USD Million (2017-2022)
  • Table 41. South Korea Acute Disease, by End-User USD Million (2017-2022)
  • Table 42. Taiwan Acute Disease, by Type USD Million (2017-2022)
  • Table 43. Taiwan Acute Disease, by Application USD Million (2017-2022)
  • Table 44. Taiwan Acute Disease, by End-User USD Million (2017-2022)
  • Table 45. Australia Acute Disease, by Type USD Million (2017-2022)
  • Table 46. Australia Acute Disease, by Application USD Million (2017-2022)
  • Table 47. Australia Acute Disease, by End-User USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Acute Disease, by Type USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Acute Disease, by Application USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Acute Disease, by End-User USD Million (2017-2022)
  • Table 51. Europe Acute Disease, by Country USD Million (2017-2022)
  • Table 52. Europe Acute Disease, by Type USD Million (2017-2022)
  • Table 53. Europe Acute Disease, by Application USD Million (2017-2022)
  • Table 54. Europe Acute Disease, by End-User USD Million (2017-2022)
  • Table 55. Germany Acute Disease, by Type USD Million (2017-2022)
  • Table 56. Germany Acute Disease, by Application USD Million (2017-2022)
  • Table 57. Germany Acute Disease, by End-User USD Million (2017-2022)
  • Table 58. France Acute Disease, by Type USD Million (2017-2022)
  • Table 59. France Acute Disease, by Application USD Million (2017-2022)
  • Table 60. France Acute Disease, by End-User USD Million (2017-2022)
  • Table 61. Italy Acute Disease, by Type USD Million (2017-2022)
  • Table 62. Italy Acute Disease, by Application USD Million (2017-2022)
  • Table 63. Italy Acute Disease, by End-User USD Million (2017-2022)
  • Table 64. United Kingdom Acute Disease, by Type USD Million (2017-2022)
  • Table 65. United Kingdom Acute Disease, by Application USD Million (2017-2022)
  • Table 66. United Kingdom Acute Disease, by End-User USD Million (2017-2022)
  • Table 67. Netherlands Acute Disease, by Type USD Million (2017-2022)
  • Table 68. Netherlands Acute Disease, by Application USD Million (2017-2022)
  • Table 69. Netherlands Acute Disease, by End-User USD Million (2017-2022)
  • Table 70. Rest of Europe Acute Disease, by Type USD Million (2017-2022)
  • Table 71. Rest of Europe Acute Disease, by Application USD Million (2017-2022)
  • Table 72. Rest of Europe Acute Disease, by End-User USD Million (2017-2022)
  • Table 73. MEA Acute Disease, by Country USD Million (2017-2022)
  • Table 74. MEA Acute Disease, by Type USD Million (2017-2022)
  • Table 75. MEA Acute Disease, by Application USD Million (2017-2022)
  • Table 76. MEA Acute Disease, by End-User USD Million (2017-2022)
  • Table 77. Middle East Acute Disease, by Type USD Million (2017-2022)
  • Table 78. Middle East Acute Disease, by Application USD Million (2017-2022)
  • Table 79. Middle East Acute Disease, by End-User USD Million (2017-2022)
  • Table 80. Africa Acute Disease, by Type USD Million (2017-2022)
  • Table 81. Africa Acute Disease, by Application USD Million (2017-2022)
  • Table 82. Africa Acute Disease, by End-User USD Million (2017-2022)
  • Table 83. North America Acute Disease, by Country USD Million (2017-2022)
  • Table 84. North America Acute Disease, by Type USD Million (2017-2022)
  • Table 85. North America Acute Disease, by Application USD Million (2017-2022)
  • Table 86. North America Acute Disease, by End-User USD Million (2017-2022)
  • Table 87. United States Acute Disease, by Type USD Million (2017-2022)
  • Table 88. United States Acute Disease, by Application USD Million (2017-2022)
  • Table 89. United States Acute Disease, by End-User USD Million (2017-2022)
  • Table 90. Canada Acute Disease, by Type USD Million (2017-2022)
  • Table 91. Canada Acute Disease, by Application USD Million (2017-2022)
  • Table 92. Canada Acute Disease, by End-User USD Million (2017-2022)
  • Table 93. Mexico Acute Disease, by Type USD Million (2017-2022)
  • Table 94. Mexico Acute Disease, by Application USD Million (2017-2022)
  • Table 95. Mexico Acute Disease, by End-User USD Million (2017-2022)
  • Table 96. Acute Disease: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Acute Disease: by Type(USD Million)
  • Table 109. Acute Disease Acute minor illness (self-limiting) , by Region USD Million (2023-2028)
  • Table 110. Acute Disease Acute major illness (self-limiting or requiring treatment) , by Region USD Million (2023-2028)
  • Table 111. Acute Disease Acute presentation of existing major illness (acute exacerbation) , by Region USD Million (2023-2028)
  • Table 112. Acute Disease Acute presentation of new chronic illness , by Region USD Million (2023-2028)
  • Table 113. Acute Disease: by Application(USD Million)
  • Table 114. Acute Disease Children , by Region USD Million (2023-2028)
  • Table 115. Acute Disease Adult , by Region USD Million (2023-2028)
  • Table 116. Acute Disease: by End-User(USD Million)
  • Table 117. Acute Disease Hospitals , by Region USD Million (2023-2028)
  • Table 118. Acute Disease Clinics , by Region USD Million (2023-2028)
  • Table 119. Acute Disease Others , by Region USD Million (2023-2028)
  • Table 120. South America Acute Disease, by Country USD Million (2023-2028)
  • Table 121. South America Acute Disease, by Type USD Million (2023-2028)
  • Table 122. South America Acute Disease, by Application USD Million (2023-2028)
  • Table 123. South America Acute Disease, by End-User USD Million (2023-2028)
  • Table 124. Brazil Acute Disease, by Type USD Million (2023-2028)
  • Table 125. Brazil Acute Disease, by Application USD Million (2023-2028)
  • Table 126. Brazil Acute Disease, by End-User USD Million (2023-2028)
  • Table 127. Argentina Acute Disease, by Type USD Million (2023-2028)
  • Table 128. Argentina Acute Disease, by Application USD Million (2023-2028)
  • Table 129. Argentina Acute Disease, by End-User USD Million (2023-2028)
  • Table 130. Rest of South America Acute Disease, by Type USD Million (2023-2028)
  • Table 131. Rest of South America Acute Disease, by Application USD Million (2023-2028)
  • Table 132. Rest of South America Acute Disease, by End-User USD Million (2023-2028)
  • Table 133. Asia Pacific Acute Disease, by Country USD Million (2023-2028)
  • Table 134. Asia Pacific Acute Disease, by Type USD Million (2023-2028)
  • Table 135. Asia Pacific Acute Disease, by Application USD Million (2023-2028)
  • Table 136. Asia Pacific Acute Disease, by End-User USD Million (2023-2028)
  • Table 137. China Acute Disease, by Type USD Million (2023-2028)
  • Table 138. China Acute Disease, by Application USD Million (2023-2028)
  • Table 139. China Acute Disease, by End-User USD Million (2023-2028)
  • Table 140. Japan Acute Disease, by Type USD Million (2023-2028)
  • Table 141. Japan Acute Disease, by Application USD Million (2023-2028)
  • Table 142. Japan Acute Disease, by End-User USD Million (2023-2028)
  • Table 143. India Acute Disease, by Type USD Million (2023-2028)
  • Table 144. India Acute Disease, by Application USD Million (2023-2028)
  • Table 145. India Acute Disease, by End-User USD Million (2023-2028)
  • Table 146. South Korea Acute Disease, by Type USD Million (2023-2028)
  • Table 147. South Korea Acute Disease, by Application USD Million (2023-2028)
  • Table 148. South Korea Acute Disease, by End-User USD Million (2023-2028)
  • Table 149. Taiwan Acute Disease, by Type USD Million (2023-2028)
  • Table 150. Taiwan Acute Disease, by Application USD Million (2023-2028)
  • Table 151. Taiwan Acute Disease, by End-User USD Million (2023-2028)
  • Table 152. Australia Acute Disease, by Type USD Million (2023-2028)
  • Table 153. Australia Acute Disease, by Application USD Million (2023-2028)
  • Table 154. Australia Acute Disease, by End-User USD Million (2023-2028)
  • Table 155. Rest of Asia-Pacific Acute Disease, by Type USD Million (2023-2028)
  • Table 156. Rest of Asia-Pacific Acute Disease, by Application USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific Acute Disease, by End-User USD Million (2023-2028)
  • Table 158. Europe Acute Disease, by Country USD Million (2023-2028)
  • Table 159. Europe Acute Disease, by Type USD Million (2023-2028)
  • Table 160. Europe Acute Disease, by Application USD Million (2023-2028)
  • Table 161. Europe Acute Disease, by End-User USD Million (2023-2028)
  • Table 162. Germany Acute Disease, by Type USD Million (2023-2028)
  • Table 163. Germany Acute Disease, by Application USD Million (2023-2028)
  • Table 164. Germany Acute Disease, by End-User USD Million (2023-2028)
  • Table 165. France Acute Disease, by Type USD Million (2023-2028)
  • Table 166. France Acute Disease, by Application USD Million (2023-2028)
  • Table 167. France Acute Disease, by End-User USD Million (2023-2028)
  • Table 168. Italy Acute Disease, by Type USD Million (2023-2028)
  • Table 169. Italy Acute Disease, by Application USD Million (2023-2028)
  • Table 170. Italy Acute Disease, by End-User USD Million (2023-2028)
  • Table 171. United Kingdom Acute Disease, by Type USD Million (2023-2028)
  • Table 172. United Kingdom Acute Disease, by Application USD Million (2023-2028)
  • Table 173. United Kingdom Acute Disease, by End-User USD Million (2023-2028)
  • Table 174. Netherlands Acute Disease, by Type USD Million (2023-2028)
  • Table 175. Netherlands Acute Disease, by Application USD Million (2023-2028)
  • Table 176. Netherlands Acute Disease, by End-User USD Million (2023-2028)
  • Table 177. Rest of Europe Acute Disease, by Type USD Million (2023-2028)
  • Table 178. Rest of Europe Acute Disease, by Application USD Million (2023-2028)
  • Table 179. Rest of Europe Acute Disease, by End-User USD Million (2023-2028)
  • Table 180. MEA Acute Disease, by Country USD Million (2023-2028)
  • Table 181. MEA Acute Disease, by Type USD Million (2023-2028)
  • Table 182. MEA Acute Disease, by Application USD Million (2023-2028)
  • Table 183. MEA Acute Disease, by End-User USD Million (2023-2028)
  • Table 184. Middle East Acute Disease, by Type USD Million (2023-2028)
  • Table 185. Middle East Acute Disease, by Application USD Million (2023-2028)
  • Table 186. Middle East Acute Disease, by End-User USD Million (2023-2028)
  • Table 187. Africa Acute Disease, by Type USD Million (2023-2028)
  • Table 188. Africa Acute Disease, by Application USD Million (2023-2028)
  • Table 189. Africa Acute Disease, by End-User USD Million (2023-2028)
  • Table 190. North America Acute Disease, by Country USD Million (2023-2028)
  • Table 191. North America Acute Disease, by Type USD Million (2023-2028)
  • Table 192. North America Acute Disease, by Application USD Million (2023-2028)
  • Table 193. North America Acute Disease, by End-User USD Million (2023-2028)
  • Table 194. United States Acute Disease, by Type USD Million (2023-2028)
  • Table 195. United States Acute Disease, by Application USD Million (2023-2028)
  • Table 196. United States Acute Disease, by End-User USD Million (2023-2028)
  • Table 197. Canada Acute Disease, by Type USD Million (2023-2028)
  • Table 198. Canada Acute Disease, by Application USD Million (2023-2028)
  • Table 199. Canada Acute Disease, by End-User USD Million (2023-2028)
  • Table 200. Mexico Acute Disease, by Type USD Million (2023-2028)
  • Table 201. Mexico Acute Disease, by Application USD Million (2023-2028)
  • Table 202. Mexico Acute Disease, by End-User USD Million (2023-2028)
  • Table 203. Acute Disease: by Type(USD/Units)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acute Disease: by Type USD Million (2017-2022)
  • Figure 5. Global Acute Disease: by Application USD Million (2017-2022)
  • Figure 6. Global Acute Disease: by End-User USD Million (2017-2022)
  • Figure 7. South America Acute Disease Share (%), by Country
  • Figure 8. Asia Pacific Acute Disease Share (%), by Country
  • Figure 9. Europe Acute Disease Share (%), by Country
  • Figure 10. MEA Acute Disease Share (%), by Country
  • Figure 11. North America Acute Disease Share (%), by Country
  • Figure 12. Global Acute Disease: by Type USD/Units (2017-2022)
  • Figure 13. Global Acute Disease share by Players 2022 (%)
  • Figure 14. Global Acute Disease share by Players (Top 3) 2022(%)
  • Figure 15. Global Acute Disease share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 19. Johnsons & Johnsons (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnsons & Johnsons (United States) Revenue: by Geography 2022
  • Figure 21. INO Therapeutics, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 22. INO Therapeutics, LLC (United States) Revenue: by Geography 2022
  • Figure 23. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Octapharma AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. Ono Pharmaceutical Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Ono Pharmaceutical Co., Ltd (Japan) Revenue: by Geography 2022
  • Figure 27. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 29. Chiesi Farmaceutici S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 30. Chiesi Farmaceutici S.p.A. (Italy) Revenue: by Geography 2022
  • Figure 31. B. Braun Melsungen (Germany) Revenue, Net Income and Gross profit
  • Figure 32. B. Braun Melsungen (Germany) Revenue: by Geography 2022
  • Figure 33. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceuticals (Israel) Revenue: by Geography 2022
  • Figure 35. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 36. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2022
  • Figure 37. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 39. Global Acute Disease: by Type USD Million (2023-2028)
  • Figure 40. Global Acute Disease: by Application USD Million (2023-2028)
  • Figure 41. Global Acute Disease: by End-User USD Million (2023-2028)
  • Figure 42. South America Acute Disease Share (%), by Country
  • Figure 43. Asia Pacific Acute Disease Share (%), by Country
  • Figure 44. Europe Acute Disease Share (%), by Country
  • Figure 45. MEA Acute Disease Share (%), by Country
  • Figure 46. North America Acute Disease Share (%), by Country
  • Figure 47. Global Acute Disease: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • Johnsons & Johnsons (United States)
  • INO Therapeutics, LLC (United States)
  • Octapharma AG (Switzerland)
  • Ono Pharmaceutical Co., Ltd (Japan)
  • Eli Lilly and Company (United States)
  • Chiesi Farmaceutici S.p.A. (Italy)
  • B. Braun Melsungen (Germany)
  • Teva Pharmaceuticals (Israel)
  • Dr. Reddy’s Laboratories (India)
  • Boehringer Ingelheim (Germany)
Additional players considered in the study are as follows:
Merck (United States) , Novartis (Switzerland) , AbbVie (United States) , AstraZeneca (United Kingdom) , GlaxoSmithKline (United Kingdom)
Select User Access Type

Key Highlights of Report


Jul 2023 222 Pages 94 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acute Disease Market Quantitative research analysis
Global Acute Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Acute Disease market are GlaxoSmithKline plc. (United Kingdom), Johnsons & Johnsons (United States), INO Therapeutics, LLC (United States), Octapharma AG (Switzerland), Ono Pharmaceutical Co., Ltd (Japan), Eli Lilly and Company (United States), Chiesi Farmaceutici S.p.A. (Italy), B. Braun Melsungen (Germany), Teva Pharmaceuticals (Israel), Dr. Reddy’s Laboratories (India) and Boehringer Ingelheim (Germany), to name a few.
is dominating the Acute Disease Market.
"Lack of awareness regarding the treatment of acute disease" is seen as one of the major challenges by many Industry Players of Acute Disease Market
The Acute Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Acute Disease market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Acute Disease Market Report?

Have a Query? Click Here

Other Related Reports

Bone Growth Stimulator Comprehensive Study by Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial, Other Applications), Stimulators (Internal Bone Growth Stimulators...
$ 3750
Cancer Therapeutics Comprehensive Study by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Other), Drug Selling (Revlimid, Avastin, Herceptin, Rituxan, Opdi...
$ 3800
Gaucher Disease Treatment Comprehensive Study by Therapy (Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others, Substrate Replacement T...
$ 3750
Post-Traumatic Stress Disorder Therapeutics Comprehensive Study by End-Users (Male, Female, Children), Drug Class (Antidepressants, Anti-anxiety Drugs, Other Drug Class) Players and Region - Global M...
$ 3500
Thalassemia Comprehensive Study by Type (Alpha-Thalassemia, Beta Thalassemia), Application (Hospital, Clinic, Research Institute, Laboratories), Treatment Type (Blood Transfusions, Iron Chelation The...
$ 3650
Melanoma Therapeutics Comprehensive Study by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiat...
$ 3750